Royalty Report: Drugs, Cancer, cell therapy – Collection: 305481

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Cancer
  • cell therapy
  • Biotechnology
  • Disease
  • Drug Discovery
  • Test/Monitoring
  • Assay
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305481

License Grant
Licensor grants a sole and exclusive worldwide license or sublicense, as applicable, to the Licensor Technology for the CPS in the Field.
License Property
The patents include  Apparatus and Method for Maintaining  and Growing Biological Cells;  Methods of Increasing Rates of !n!ection by Directing Motion of Vectors;  Methods, Compositions and Apparatus for Cell Transfection; and, Methods, Compositions and Devices for Maintaining and Growing Human Stem and/or Hematopoietic Cells.

CPS means any system or device for substantially increasing, the number of cells, ex vivo, for human therapeutic uses, that may be configured in different component structures (such as described for the Automated CPS or the Manual CPS).

Licensed Product means the Automated CPS (both the Durables and the Disposables) as used for one or more specific Lymphoid Cell Applications.

Licensor is developing proprietary process technologies and devices for a range of cell therapy applications, including stem cell therapies and gene therapy. The lead product under development, the Licensors Cell Production System (the CPS) consists of a clinical cell culture system with disposable cassettes and reagents for use in the rapidly growing stem cell therapy market.

Field of Use
Field means Lymphoid Cell Applications.  Application means (a) the expansion of any Lymphoid Cell for one or more therapeutic uses, or (b) the transfection of a specific Lymphoid Cell type modified with a naturally occurring gene or a synthetic modification thereof for a specific therapeutic use. One Application is tumor infiltrating lymphocytes (TIL), such that TIL therapy for renal cell carcinoma and TIL therapy for breast cancer are part of the same Application.

Licensee, a competitor, along with others, are in advanced stages of development of technologies and products for use in stem cell therapy and other market applications currently being pursued by the Licensor.

IPSCIO Record ID: 336552

License Grant
Licensor of United Kingdom, whose key founders are also shareholders of the Licensee, pursuant to which the Licensee obtained a worldwide license to Licensor’s proprietary technology, know-how and intellectual property for the research, development and manufacture of TIL therapies obtained from tumors using Licensor’s technology.
License Property
TIL are tumor infiltrating lymphocyte therapies.

Tumor-infiltrating lymphocytes are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, (i.e., T cells, B cells, natural killer cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, basophils, etc.) in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis

Field of Use
Tumor infiltrating lymphocyte or TIL is therapies for the treatment of patients with cancer.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 2705

License Grant
The University hereby grants to Licensee an exclusive world-wide license, without the right to grant sublicenses,  under Licensed Patents and to use Know-How to make, use, and sell Product(s), except that University hereby retains the right to use Licensed Patents and Know-How solely for research purposes, and except that to the extent funding from federal agencies results in Licensed Technology or Licensed Patents in addition to Project funding, the federal government may have its standard license rights with respect to such Licensed Technology or Licensed Patents.
License Property
'Licensed Technology' means all patentable inventions and Know-how for the production of red blood cells, white blood cells, platelets and bone marrow cells, which are either described in University Project proposal, or conceived or reduced to practice as part of Project, or conceived or reduced to practice, whether or not pursuant to or as part of the Project.

'Product(s)' means any red blood cells, white blood cells, platelets and bone marrow cells as well as any components, by-products, progeny or derivatives thereof and any factor, composition, substance, equipment, mechanism, device or other property and combinations thereof, the manufacture, use or sale of which would, but for this License, comprise an infringement of one or more Valid Claims.

Field of Use
A.  U.S. APPLICATION, SER. #07/366,639, OSMMN REF. #2363-022-55

        Methods, Compositions and Devices for Growing Cells.

        Filed  6/15/89

    B.  U.S. APPLICATION, SER. #07/628,343, OSMMN REF. #2363-023-55 CIP

        Methods and Compositions for the Ex Vivo Replication of Stem Cells

        and for the Optimization of Hematopoietic Progenitor Cell Cultures.

        Filed  12/17/90

    E.  U.S. APPLICATION, SER. #07/737,024, OSMMN REF. #2363-034-55

        Methods and Compositions for the Ex Vivo Replication of Stem Cells,

        for the Optimization of Hematopoietic Progenitor Cell Cultures,

        and for Increasing the Metabolism, GM-CSF Secretion and/or IL-6

        Secretion of Human Stromal Cells.

        Filed 7/29/91

    F.  U.S. APPLICATION, SER. #07/740,590, OSMN REF. #2363-035-55

        Methods for Human Gene Therapy, Including Methods and Compositions

        for the Ex Vivo Replication and Stable Genetic Transformation of Human

        Stem Cells, for the Optimization of Human Hematopoietic Progenitor Cell

        Cultures and Stable Genetic and/or IL-6 Secretion of Human Stromal

        Cells.

        Filed 8/5/91

    H.  U.S. APPLICATION, SER. #07,815,513, OSMMN REF. #2363-036-55

        Methods for Regulating the Specific Lineages of Cells Produced in

        a Human Hematopoietic Cell Culture, Methods for Assaying the Effect

        of Substances on Lineage-Specific Cell Production, and Cell Compositions

        Produced by these Cultures.

        Filed  1/2/92

    I.  U.S. APPLICATION, SER. #07/822,136, OSMMN REF. #2363-055-55

        Targeted Virus.

        Filed  1/17/92

    J.  PENDING U.S. APPLICATION, OSMMN REF. #2363-043-55

        Methods, Compositions and Devices for Maintaining and Growing Human

        Stem and/or Hematopoietic Cells.

        Filed  3/4/92

IPSCIO Record ID: 274909

License Grant
Licensor grants to the Licensee of the United Kingdom, and its Affiliates, an exclusive license under Licensor Background Patent Rights, Licensor Future Patent Rights, Licensor Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights, and Licensor Know-How to develop, have developed, make, have made, use, sell, have sold, and import Cellular Assay Products throughout the Territory in the Cellular Assay Products Field.

Licensor grants
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights and Licensor’s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.

Licensor grants an option to negotiate in good faith and on commercially reasonable terms
—  an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensor’s interest in Joint Alliance IP Rights, and;
—  a sub-license for the Cellular Assay Products Field in the Territory.

License Property
The patents and know-how are for certain intellectual property rights related to the propagation and differentiation of human embryonic derived cells.
Field of Use
The Cellular Assay Products Field shall mean the use of Cellular Assay Products for in vitro assay applications, including but not limited to drug discovery and development, drug monitoring, drug toxicology testing, and consumer products testing, but excluding the use of any Cellular Assay Product in any therapeutic or diagnostic application.

The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.

The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.

Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.

IPSCIO Record ID: 324365

License Grant
According to the agreement, the Licensees U.S. Subsidiary was granted a worldwide, royalty bearing, exclusive license from the Israeli Licensor, an affiliate of university,  to develop and commercialize technology directed to RAFT modification of polysaccharides and use of a bioreactor for supporting cell constructs.
License Property
Bioreactors and polysaccharides are part of the Cell & Gene Therapy Platform.

Bioreactors is for cell culture.

Polysaccharides is part of the Scaffold group. Scaffolds, including alginate and sulfated alginate scaffolds, polysaccharides thereof, and scaffolds for use for cell propagation, trans-differentiation, and transplantation in the treatment of autoimmune diseases.

Field of Use
The field of use is for the treatment of autoimmune diseases and to identify the most promising new autologous therapies and provide a pathway for them to reach patients more quickly, more efficiently and in a scalable way, thereby unlocking the power of cell and gene therapy for all patients. A wide range of therapies and supporting technologies include, but not limited to, Tumor Infiltrating Lymphocytes (“TILs”), CAR-T and CAR-NK, dendritic cell technologies, exosomes and bioxomes and viral vectors.

RUXIENCE is approved in the US for treating chronic Lymphotic leukemia, non-Hodgkin’s lymphoma, Microscopic Polyangiitis with glucocorticoids, and Granulomatosis with Polyangiitis.

Microscopic polyangiitis (MPA) is a condition that causes small blood vessels to be inflamed. It's a rare type of vasculitis. The disease can damage the blood vessels and cause problems in organs around the body. MPA most often affects people in their 50s and 60s, but it can happen in people of any age.

Granulomatosis with polyangiitis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs and kidneys. Formerly called Wegener's granulomatosis, this condition is one of a group of blood vessel disorders called vasculitis. It slows blood flow to some of your organs.

IPSCIO Record ID: 372470

License Grant
The University grants a license under the Biological Material in the Licensed Field of Use to make, have made, use, have used, import, have imported, offer to sell, have offered to sell, sell and have sold Licensed Product in the Licensed Territory.  The license is nonexclusive in the Licensed Field of Use.
License Property
The University has rights to biological material known as 293T Cell Line.

The HEK293T cells are maintained in disposable flasks until sufficient cell mass has been generated to fill approximately 40 ten tray cell factories, or TTCFs, then transferred and allowed to adhere to the bottom of the trays.  Adherent cells are transfected with multiple plasmids encoding all the genetic material required to assemble the lentiviral vector carrying the functional gene of interest.  The transfected HEK293T cells then assemble our lentiviral vectors packaged with the functional gene of interest, which bud off into the cell culture media. The media containing the assembled vectors is harvested, purified, concentrated and formulated prior to freezing for storage. These finished lentiviral vectors are what is ultimately used to transduce the targeted cells isolated from the patient.

Field of Use
Licensed Field of Use means any commercial and/or non-commercial use of Biological Material for
• research, and non-clinical and clinical development purposes; and
• human and animal gene therapy products.

IPSCIO Record ID: 26263

License Grant
Licensor hereby grants to Licensee, a royalty bearing, exclusive, worldwide License in the Field of  research, development, manufacture and selling of human cells for cell therapy in the treatment of human diabetes and liver diseases.
License Property
The Technology is to research, develop, make, have made, use, sell, offer for sale, import and export Licensed Products, Processes and Services to produce human embryonic stem cells and to produce from those mammalian embryonic cells, differentiated cells for human cell therapy within the Field, and to produce pluripotent cells including ES cells, differentiated human cells for cell therapy within the field.

5,453,366 Method of Cloning Bovine Embryos

6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells

6,258,998 Method of Cloning Porcine Animals

5,843,754 Parthenogenic Bovine Oocyte Activation

5,496,720 Parthenogenic Oocyte Activation

09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.

6,194,202 Parthenogenic Oocyte Activation

6,077,710  Parthenogenic Oocyte Activation

6,107,543  Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
Animals

Field of Use
The Field shall exclude applications involving the use of cells in the treatment of tumors where the primary use of the cells is the destruction or reduction of tumors and does not involve regeneration of tissue or organ function.

IPSCIO Record ID: 248290

License Grant
This amendment modifies the list of patents and adds sublicense clarifications. For clarity,  sales of Licensed Products by Licensee or its Affiliate to a Sublicensee for resale by such Sublicensee are not included in Net Sales,  sales of Licensed Products by a Sub licensee (including those Licensed Products purchased from Licensee or its Affiliates) to a Third Party that is not an Affiliate of such Sublicensee are included in Net Sales, and in the event that Licensee or an Affiliate of Licensee grants rights.
License Property
The amended list of patents include, but are not limited to Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase;  Method for Tumor Treatment Using Infusion of Xenogeneic Cells to Induce Hyperacute Rejection and Innocent Bystander Effect;  Methods and Comp__ositions for Inducing Complement Destruction of Tissue;  and,  Herpes SimJ!lex Virus Amplicon Mini-Vector Gene Transfer System.
Field of Use
The patents are for cell therapies for tumor treatment.

IPSCIO Record ID: 245925

License Grant
Licensor hereby grants Licensee a nonexclusive license under the Licensed Patent Rights and the Licensed Technology to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory. The license shall include, without limitation, the right to (i) sell Products to purchasers and/or distributors in the Field and in the Territory and/or (ii) to collaborate with preclinical or clinical investigators in the Field and in the Territory provided such investigators are bound by the confidentiality provisions contained herein, and/or (iii) to sublicense to Affiliates of Licensee, to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory, provided that such Affiliates will be bound by the terms and conditions contained herein and/or (iv) to sublicense to Third Parties to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory for use in combination with Licenseel Technology, provided such Third Party sublicensee shall be identified to Licensor and be bound by the applicable terms and conditions as contained herein.
License Property
Licensed Patent Rights shall be as defined
5,869,451 – Peptides and compounds that bind to a receptor
6,121,238 – Peptides and compounds that bind to a receptor
6,251,864 – Peptides and compounds that bind to a receptor
6,083,913 – Peptides and compounds that bind to a thrombopoietin receptor
5,932,546 – Peptides and compounds that bind to the thrombopoietin receptor

Licensed Technology shall mean the technology, know-how, data, information and results relating to the synthesis and characterization of Licensed Compound to be supplied to Licenseel, as referred to Pre-Clinical Evaluation of Tpo Mimetic Peptides Index to Analysis, Biology, Formulation, Pharmacology, Synthesis and DMPK.

Licensed Compound shall mean any composition of matter which uses and/or comprises the AF13948, AF15705, GW350805 and/or GW395058 compounds.

Product shall mean any cellular therapy or gene therapy product developed or manufactured using a Licensed Compound, for which the use of the Licensed Compound would, but for the license granted hereunder, otherwise infringe a Valid Claim of the Licensed Patent Rights.

Thrombopoietin mimetics are drugs that considerably increase platelet production by stimulating the receptor for the hormone thrombopoietin.

Field of Use
Field shall mean ex vivo cell therapy and ex vivo gene therapy. The Field excludes parenteral or in vivo therapies, which are expressly reserved for Licensor or such third parties to whom such uses may be licensed by Licensor, provided that the Field shall include ex vivo and extra-corporeal uses where the primary intended activity of the Licensed Compound is ex vivo and any residuals thereof which may be introduced in vivo have no significant medical or therapeutic benefit. 'Extra-corporeal' means a process where a patients cells are extracted, processed and infused back into a subject by a device while the subject remains connected to the device.

The forms of TPO-mimetic is for use as a reagent in producing stem cell therapy products, including CB001.

CB001 is manufactured using one of Licensee's proprietary technologies which allows the isolation, purification and significant expansion of populations of stem cells. Licensee believe this proprietary technology will enable the production of well defined cellular products in therapeutically useful quantities. We are developing CB001 for use in bone marrow and other hematopoietic stem cell transplants.  CB001 has entered a Phase I/II clinical trial in older adolescents and adults.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.